Usted buscó: nateglinide (Inglés - Croata)

nateglinide is extensively metabolised.
nateglinid se ektenzivno metabolizira.

starlix 120 mg tablets nateglinide
starlix 120 mg tablete nateglinid

nateglinide was not teratogenic in rats.
nateglinid nije bio teratogen u štakora.

nateglinide should not be used in monotherapy.
nateglinid se ne smije koristiti u monoterapiji.

starlix 120 mg film-coated tablets nateglinide
starlix 120 mg filmom obložene tablete nateglinid

each tablet contains 60, 120 or 180 mg nateglinide.
svaka tableta sadrži 60, 120 ili 180 mg nateglinida.

1 film-coated tablet contains 120 mg nateglinide.
1 filmom obložena tableta sadrži 120 mg nateglinida.

nateglinide and its metabolites are rapidly and completely eliminated.
nateglinid i njegovi metaboliti eliminiraju se brzo i potpuno.

metformin, liraglutide, vildagliptin, nateglinide (antidiabetic medicines);
metformin, liraglutid, vildagliptin, nateglinid (antidijabetici),

nateglinide is a rapid, short-acting oral insulin secretagogue.
nateglinid je brzi, kratkodjelujući oralni stimulator sekrecije inzulina.

like other insulin secretagogues, nateglinide is capable of producing hypoglycaemia.
poput ostalih stimulatora sekrecije inzulina, nateglinid može uzrokovati hipoglikemiju.

nateglinide should be used with caution in patients with moderate hepatic impairment.
nateglinid treba koristiti oprezno u bolesnika s umjerenim oštećenjem jetre.

conversely, these medicinal products had no effect on the pharmacokinetics of nateglinide.
vrijedi i obrnuto, ti lijekovi nisu utjecali na farmakinetiku nateglinida.

no clinically significant differences in nateglinide pharmacokinetics were observed between men and women.
nisu bile uočene nikakve klinički značajne razlike u farmakokinetici nateglinida između muškaraca i žena.

insulin; metformin, liraglutide, vildagliptin, nateglinide (antidiabetic medicines).
inzulin; metformin, liraglutid, vildagliptin, nateglinid (antidijabetici).

as patients with severe liver disease were not studied, nateglinide is contraindicated in this group.
budući da bolesnici s teškom bolešću jetre nisu ispitivani, nateglinid je u toj skupini kontraindiciran.

as with other antidiabetic agents, symptoms suggestive of hypoglycaemia have been observed after administration of nateglinide.
kao što je slučaj i s drugim antidijabeticima, nakon uzimanja nateglinida uočeni su simptomi koji upućuju na hipoglikemiju.

in vivo, nateglinide has no clinically relevant effect on the pharmacokinetics of medicinal products metabolised by cyp2c9 and cyp3a4.
in vivo, nateglinid nema klinički značajan učinak na farmakokinetiku lijekova koji se metaboliziraju putem cyp2c9 i cyp3a4.

as nateglinide is highly protein-bound, dialysis is not an efficient means of removing it from the blood.
budući da je nateglinid vezan za proteine u visokom postotku, dijaliza nije učinkovit način uklanjanja nateglinida iz krvi.

data available from both in vitro and in vivo experiments indicate that nateglinide is predominantly metabolised by cyp2c9 with involvement of cyp3a4 to a smaller extent.
dostupni podaci iz in vitro i in vivo ispitivanja upućuju da se nateglinid uglavnom metabolizira putem cyp2c9, uz uključenost cyp3a4 u manjoj mjeri.